Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study
Authors' conclusion
This post hoc analysis found that higher doses of zalunfiban administered in the cardiac catheterization lab prior to vascular access were associated with greater coronary and myocardial perfusion, and lower thrombus burden at initial angiogram in patients with STEMI undergoing primary percutaneous coronary intervention.
Study context
- Population
- ST-elevation myocardial infarction (STEMI) patients; zalunfiban given in cath lab before vascular access, ∼10 to 15 minutes before initial angiogramTwentyfour evaluable for angiography
- Participants
- 27 patients
- Comparison
- Zalunfiban 0.075 vs 0.090 vs 0.110 mg/kg
- 0.075 mg/kgn = 7
- 0.090 mg/kgn = 9
- 0.110 mg/kgn = 8
- Primary endpoint
- Dose-dependent association with infarct-related artery (IRA) angiographic indices (coronary and myocardial blood flow, thrombus burden)
- Follow-up
- Initial angiogram
Methodological detailsblinded independent core laboratory, All angiographic data analysed by a blinded, independent, core laboratory
- Blinded independent core laboratory
- All angiographic data analysed by a blinded, independent, core laboratory
Primary result
As reported in the abstract
TIMI flow grade 2 or 3
0.075 mg/kg
1 of 7
events
0.090 mg/kg
6 of 9
events
0.110 mg/kg
7 of 8
events
P for trend = 0.004
- TIMI myocardial perfusion grade 3 more frequent with higher dose
- P for trend = 0.005
- TIMI thrombus ≥4 grade inversely related to dose
- P for trend = 0.02
Original publication
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study. Am Heart J. Published 22 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →